Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nivolumab · 1 trial · 1 indication
To compare progression free survival in patients with on-treatment-ctDNA guided therapy continuation or escalation by addition of platinum-doublet chemotherapy to therapy continuation with Nivolumab-Ipilimumab regardless of on-treatment-ctDNA results.
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Arm A - Intervention arm (Immunotherapy and Chemotherapy) Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks Platinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion. Carboplatin dosed at AUC 5, and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous |
| Arm B | OTHER | Arm B - control arm (Immunotherapy only) Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks |
| Name | Type | Description |
|---|---|---|
| Nivolumab | DRUG | Immunotherapy |
| Ipilimumab | DRUG | Immunotherapy |
| Carboplatin | DRUG | Chemotherapy |
| Paclitaxel | DRUG | Chemotherapy |
| Pemetrexed | DRUG | Chemotherapy |
Inclusion Criteria: 1. Eligible patients will have newly diagnosed, previously untreated histologically documented Stage IV NSCLC 2. Eligible patients will be required to have positive PD-L1 expression ≥1% by IHC using Dako 22C3 assay. 3. Patients will require a baseline Guardant360 CDx test prior ...
Nivolumab is being studied for the treatment of non-small-cell lung carcinoma. It is an investigational therapy currently in Phase 2 clinical development for this indication. The drug is being evaluated in a clinical trial that enrolls patients with advanced non-small-cell lung cancer.
Nivolumab is a monoclonal antibody, classified as a -mab (antibody) modality. It is being investigated for its role in cancer immunotherapy, specifically in non-small-cell lung carcinoma. The drug is part of an active clinical trial studying immune profile selection in patients with advanced non-small-cell lung cancer.
Nivolumab is being developed by Meridian Bioscience Inc, which trades under the ticker VIVO. The company is conducting a Phase 2 clinical trial for the drug in non-small-cell lung carcinoma. The trial is currently recruiting participants in the United States.
Nivolumab is in Phase 2 clinical development for non-small-cell lung carcinoma. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting patients with advanced non-small-cell lung cancer.
Nivolumab is being studied in a Phase 2 clinical trial with the identifier NCT05715229. The trial is titled "Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy." It is recruiting 108 participants in the United States and is actively enrolling patients aged 18 years and older.
Nivolumab is a distinct drug candidate being developed by Meridian Bioscience Inc. It is a small molecule with a monoclonal antibody modality. No alternative names for this drug have been disclosed in the available information.